Inmed Pharmaceuticals Stock Price on October 25, 2024
| INM Stock | USD 4.29 0.01 0.23% |
Below is the normalized historical share price chart for InMed Pharmaceuticals extending back to November 21, 2001. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of InMed Pharmaceuticals stands at 4.29, as last reported on the 1st of December, with the highest price reaching 4.48 and the lowest price hitting 4.29 during the day.
If you're considering investing in InMed Stock, it is important to understand the factors that can impact its price. InMed Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.0556, which attests that the entity had a -0.0556% return per unit of volatility over the last 3 months. InMed Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out InMed Pharmaceuticals' market risk adjusted performance of (3.03), and Risk Adjusted Performance of (0.06) to validate the risk estimate we provide.
At this time, InMed Pharmaceuticals' Total Stockholder Equity is very stable compared to the past year. As of the 1st of December 2024, Common Stock Shares Outstanding is likely to grow to about 8 M, while Common Stock is likely to drop about 53.5 M. . As of the 1st of December 2024, Price To Sales Ratio is likely to drop to 0.86. In addition to that, Price Earnings Ratio is likely to grow to -1.18. InMed Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 12th of November 2020 | 200 Day MA 5.5931 | 50 Day MA 4.8214 | Beta 0.711 |
InMed |
Sharpe Ratio = -0.0556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INM |
Estimated Market Risk
| 6.69 actual daily | 59 59% of assets are less volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average InMed Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InMed Pharmaceuticals by adding InMed Pharmaceuticals to a well-diversified portfolio.
Price Book 0.3669 | Enterprise Value Ebitda 0.9967 | Price Sales 0.6716 | Shares Float 13.3 M | Wall Street Target Price 20 |
Related Headline
Enliven Therapeutics Headline on 25th of October 2024
Richard A. Heyman Sells 817 Shares of Enliven Therapeutics, ... by thelincolnianonline.com
Enliven Therapeutics, Inc. Director Richard A. Heyman sold 817 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of 30.00, for a total transaction of 24,510.00. Following the completion of the sale, the director now owns 123,673 shares in
InMed Pharmaceuticals Valuation on October 25, 2024
It is possible to determine the worth of InMed Pharmaceuticals on a given historical date. On October 25, 2024 InMed was worth 5.66 at the beginning of the trading date compared to the closed value of 6.66. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of InMed Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find InMed Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of InMed Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against InMed Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 5.80 | 6.00 | 5.50 | 5.80 | 22,980 | |
10/25/2024 | 5.66 | 7.16 | 5.66 | 6.66 | 81,700 |
| 6.88 | 7.16 | 6.42 | 7.10 | 195,800 |
| Backtest InMed Pharmaceuticals | | | InMed Pharmaceuticals History | | | InMed Pharmaceuticals Valuation | Previous | Next |
InMed Pharmaceuticals Trading Date Momentum on October 25, 2024
| On October 28 2024 InMed Pharmaceuticals was traded for 7.10 at the closing time. Highest InMed Pharmaceuticals's price during the trading hours was 7.16 and the lowest price during the day was 6.42 . The net volume was 195.8 K. The overall trading history on the 28th of October contributed to the next trading period price boost. The trading delta at closing time to the next next day price was 6.61% . The trading delta at closing time to current price is 20.72% . |
InMed Pharmaceuticals Fundamentals Correlations and Trends
By evaluating InMed Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. InMed financial account trend analysis is a perfect complement when working with valuation or volatility modules.About InMed Pharmaceuticals Stock history
InMed Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for InMed is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in InMed Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing InMed Pharmaceuticals stock prices may prove useful in developing a viable investing in InMed Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 7.6 M | 8 M | |
| Net Loss | -7.2 M | -7.5 M |
InMed Pharmaceuticals Quarterly Net Working Capital |
|
InMed Pharmaceuticals Stock Technical Analysis
InMed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
InMed Pharmaceuticals Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
InMed Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
InMed Pharmaceuticals December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how InMed Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading InMed Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying InMed Pharmaceuticals stock market strength indicators, traders can identify InMed Pharmaceuticals entry and exit signals to maximize returns
InMed Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for InMed Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of InMed Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of InMed to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.70) | |||
| Total Risk Alpha | (1.82) | |||
| Treynor Ratio | (3.04) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.